Ask a doctor about a prescription for TIXTAR 550 MG FILM-COATED TABLETS
Package Leaflet: Information for the User
TIXTAR 550 mg film-coated tablets
rifaximin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
TIXTAR contains the active substance rifaximin. Rifaximin is an antibiotic that eliminates bacteria that can cause a disease called hepatic encephalopathy (symptoms include agitation, confusion, muscle problems, difficulty speaking, and in some cases, coma).
TIXTAR is used in adults with liver disease to reduce the recurrence of episodes of overt hepatic encephalopathy.
TIXTAR may be used alone or, more commonly, in combination with medications that contain lactulose (a laxative).
Do not take TIXTAR:
-rifaximin
-similar antibiotics (such as rifampicin or rifabutin)
-any of the other components of this medicine (listed in section 6)
Warnings and precautions
Consult your doctor or pharmacist before starting to take TIXTAR.
If you have ever developed a severe skin rash or skin peeling, blisters, and/or sores in the mouth after taking rifaximin.
Be careful with rifaximin:
Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with rifaximin treatment. Stop using rifaximin and seek immediate medical attention if you notice any of the symptoms related to these severe skin reactions described in section 4.
While taking TIXTAR, your urine may turn reddish. This is normal.
Treatment with any antibiotic, including rifaximin, can cause severe diarrhea. This can happen several months after you have finished taking the medicine. If you have severe diarrhea during or after using TIXTAR, you should stop taking TIXTAR and contact your doctor immediately.
If your liver problems are severe, your doctor should keep you under close observation.
TIXTAR contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Children and adolescents
TIXTAR is not recommended for children and adolescents under 18 years of age. This medicine has not been studied in children and adolescents.
Other medicines and TIXTAR
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Tell your doctor if you are taking any of the following medicines:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is not known if TIXTAR can harm the fetus. Therefore, TIXTAR should not be used if you are pregnant.
It is not known if rifaximin can pass into breast milk. Therefore, TIXTAR should not be used if you are breastfeeding.
Driving and using machines
TIXTAR normally does not affect your ability to drive and use machines, but it can cause dizziness in some patients. If you feel dizzy, do not drive or operate machinery.
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 1 tablet twice a day taken with a glass of water.
Continue taking TIXTAR until your doctor tells you to stop.
If you take more TIXTAR than you should
If you have taken more tablets than you should, even if you do not notice any problems, consult your doctor, pharmacist, or call the Toxicology Information Service, phone 91-562 04 20, indicating the medicine and the amount taken.
If you forget to take TIXTAR
Take the next dose at the usual time. Do not take a double dose to make up for forgotten doses.
If you stop taking TIXTAR
Do not stop taking TIXTAR without consulting your doctor first, because the symptoms may come back.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop using TIXTAR and seek immediate medical attention if you notice any of the following symptoms:
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
Other side effects that may occur:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Agency's website: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month shown.
TIXTAR does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of TIXTAR
The active substance is rifaximin. Each tablet contains 550 mg of rifaximin.
The other ingredients are:
Appearance of the product and pack contents
Film-coated tablets, oval, convex, and pink, with "RX" engraved on one side.
TIXTAR is available in packs of 14, 28, 42, 56, and 98 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Alfasigma S.p.A.
Via Ragazzi del ’99, n. 5
40133 Bologna, ITALY
Manufacturer:
Alfasigma, S.p.A.
Via Enrico Fermi, 1
65020 Alanno, Pescara, ITALY
Alfasigma, S.p.A.
Via Pontina Km 30,400
00071 Pomezia, Rome, ITALY
Local representative:
Alfasigma España, S.L.
C/ Aribau 195, 4º
08021 Barcelona, SPAIN
This medicine is authorized in the Member States of the European Economic Area under the following names:
TIXTAR: Italy, Spain
Date of last revision of this leaflet: May 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)http://www.aemps.gob.es/
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TIXTAR 550 MG FILM-COATED TABLETS – subject to medical assessment and local rules.